COST-EFFECTIVENESS OF LEVETIRACETAM FOR PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY: A MODELING APPROACH BY THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

被引：0

作者：

Kayo, M. ^{[1
]}

Rosim, R. P. ^{[2
]}

Duva, A. ^{[2
]}

Ballalai Ferraz, A. F. ^{[2
]}

Carmo, E. ^{[1
]}

机构：

[1] UCB Biopharma LTDA, Sao Paulo, Brazil

[2] QuintilesIMS, Sao Paulo, Brazil

来源：

VALUE IN HEALTH | 2017年 / 20卷 / 09期

关键词：

D O I：

10.1016/j.jval.2017.08.1944

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND30

引用

页码：A722 / A723

页数：2

共 50 条

[11] COST-EFFECTIVENESS OF SAPIEN® TRANSCATHETER AORTIC VALVE FOR SEVERE SYMPTOMATIC AORTIC STENOSIS IN INOPERABLE PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Paladini, L.
Nishikawa, A. M.
Lemos, P.
Queiroga, M.
Clark, O. A. C.
VALUE IN HEALTH, 2013, 16 (03) : A288 - A289
[12] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Holanda, P.
Salgado De Santana, C.
Senna, T.
Carmo, L.
Alexandre, R. F.
VALUE IN HEALTH, 2021, 24 : S96 - S96
[13] COMPARING THE COST-EFFECTIVENESS OF APCC VS RFVIIA IN ON-DEMAND TREATMENT OF BLEEDS IN HEMOPHILIA A PATIENTS WITH INHIBITORS: A BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Carmo, E., V
Oladapo, A. O.
Rothschild, C.
VALUE IN HEALTH, 2015, 18 (07) : A666 - A666
[14] COST-EFFECTIVENESS ANALYSIS OF THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (ALTEPLASE) FOR ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Teich, V
Passos, R. B. F.
Vianna, D.
VALUE IN HEALTH, 2009, 12 (07) : A503 - A503
[15] COST-EFFECTIVENESS EVALUATION OF AMPHOTERICIN B, AMPHOTERICIN B LIPOSOMAL, CASPOFUNGIN AND VORICONAZOL IN TREATING ASPERGILLOSIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Fujii, R. K.
Manfrin, D. F.
Lanzara, G. D. A.
Hajek, P.
Mould, J.
VALUE IN HEALTH, 2013, 16 (03) : A89 - A89
[16] COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Souza, P.
Puopolo, G. R.
Leme-Souza, R.
VALUE IN HEALTH, 2019, 22 : S847 - S847
[17] THE COST EFFECTIVENESS OF OXYCODONE IN PATIENTS WHO DO NOT RESPOND TO MORPHINE FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Souza, D. A.
Aguiar, E. C.
Miguel, A. K.
Rosim, R. P.
Ballalai Ferraz, A. F.
VALUE IN HEALTH, 2017, 20 (09) : A894 - A894
[18] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS OLANZAPINE, QUETIAPINE AND ZIPRAZIDONE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Nishikawa, A. M.
Clark, O. A. C.
Pititto, L.
VALUE IN HEALTH, 2014, 17 (03) : A217 - A217
[19] COST-EFFECTIVENESS OF PALIVIZUMAB USE IN HIGH RISK CHILDREN FROM BRAZILIAN HEALTH SYSTEM PERSPECTIVE
Fernandes, R. R. A.
VALUE IN HEALTH, 2014, 17 (07) : A510 - A510
[20] COST-EFFECTIVENESS OF TRANSCATHETER AORTIC-VALVE IMPLANTATION FOR SEVERE SYMPTOMATIC AORTIC STENOSIS IN INOPERABLE PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
Nishikawa, A. M.
Paladini, L.
Borges, L.
Queiroga, M.
Lemos, P.
Clark, O. A. C.
VALUE IN HEALTH, 2013, 16 (07) : A705 - A706

← 1 2 3 4 5 →